Dolby Laboratories [DLB] vs Copart [CPRT] Detailed Stock Comparison
Dolby Laboratories
NYSE
Loading...
Copart
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Dolby Laboratories wins in 11 metrics, Copart wins in 8 metrics, with 0 ties. Dolby Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Dolby Laboratories | Copart | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 25.86 | 30.14 | Dolby Laboratories |
| Price-to-Book Ratio | 2.58 | 5.01 | Dolby Laboratories |
| Debt-to-Equity Ratio | 1.50 | 1.15 | Copart |
| PEG Ratio | 18.40 | 26.16 | Dolby Laboratories |
| EV/EBITDA | 16.12 | 20.88 | Dolby Laboratories |
| Profit Margin (TTM) | 19.62% | 32.21% | Copart |
| Operating Margin (TTM) | 14.92% | 37.27% | Copart |
| EBITDA Margin (TTM) | 14.92% | 37.27% | Copart |
| Return on Equity | 10.50% | 18.44% | Copart |
| Return on Assets (TTM) | 5.86% | 12.02% | Copart |
| Free Cash Flow (TTM) | $297.25M | $961.57M | Copart |
| 1-Year Return | -8.07% | -12.02% | Dolby Laboratories |
| Price-to-Sales Ratio (TTM) | 4.99 | 9.59 | Dolby Laboratories |
| Enterprise Value | $6.07B | $39.74B | Copart |
| EV/Revenue Ratio | 4.50 | 8.66 | Dolby Laboratories |
| Gross Profit Margin (TTM) | 86.06% | 45.58% | Dolby Laboratories |
| Revenue per Share (TTM) | $14 | $5 | Dolby Laboratories |
| Earnings per Share (Diluted) | $2.71 | $1.51 | Dolby Laboratories |
| Beta (Stock Volatility) | 0.91 | 1.07 | Dolby Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Dolby Laboratories vs Copart Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Dolby Laboratories | -6.97% | -8.21% | -7.25% | -7.99% | -16.70% | -9.90% |
| Copart | 0.40% | -2.53% | -8.32% | -24.78% | -21.21% | -19.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Dolby Laboratories | -8.07% | -10.63% | -0.11% | 105.42% | 11.50% | 270.65% |
| Copart | -12.02% | 40.85% | 83.43% | 906.86% | 1,959.28% | 2,913.91% |
Performance & Financial Health Analysis: Dolby Laboratories vs Copart
| Metric | DLB | CPRT |
|---|---|---|
| Market Information | ||
| Market Cap | $6.72B | $44.01B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 358,840 | 5,940,840 |
| 90 Day Avg. Volume | 373,870 | 7,150,000 |
| Last Close | $70.09 | $45.51 |
| 52 Week Range | $66.35 - $89.66 | $45.05 - $64.38 |
| % from 52W High | -21.83% | -29.31% |
| All-Time High | $104.74 (May 03, 2021) | $64.38 (Nov 25, 2024) |
| % from All-Time High | -33.08% | -29.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.08% |
| Quarterly Earnings Growth | 0.20% | 0.06% |
| Financial Health | ||
| Profit Margin (TTM) | 0.20% | 0.32% |
| Operating Margin (TTM) | 0.15% | 0.37% |
| Return on Equity (TTM) | 0.11% | 0.18% |
| Debt to Equity (MRQ) | 1.50 | 1.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $27.19 | $9.08 |
| Cash per Share (MRQ) | $7.30 | $4.53 |
| Operating Cash Flow (TTM) | $465.54M | $1.80B |
| Levered Free Cash Flow (TTM) | $375.60M | $873.61M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Dolby Laboratories vs Copart
| Metric | DLB | CPRT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 25.86 | 30.14 |
| Forward P/E | 18.40 | 26.16 |
| PEG Ratio | 18.40 | 26.16 |
| Price to Sales (TTM) | 4.99 | 9.59 |
| Price to Book (MRQ) | 2.58 | 5.01 |
| Market Capitalization | ||
| Market Capitalization | $6.72B | $44.01B |
| Enterprise Value | $6.07B | $39.74B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.50 | 8.66 |
| Enterprise to EBITDA | 16.12 | 20.88 |
| Risk & Other Metrics | ||
| Beta | 0.91 | 1.07 |
| Book Value per Share (MRQ) | $27.19 | $9.08 |
Financial Statements Comparison: Dolby Laboratories vs Copart
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DLB | CPRT |
|---|---|---|
| Revenue/Sales | $369.56M | $1.21B |
| Cost of Goods Sold | $35.84M | $659.45M |
| Gross Profit | $333.72M | $552.27M |
| Research & Development | $61.71M | N/A |
| Operating Income (EBIT) | $111.97M | $451.55M |
| EBITDA | $140.61M | $506.07M |
| Pre-Tax Income | $120.25M | $502.80M |
| Income Tax | $28.02M | $97.47M |
| Net Income (Profit) | $92.23M | $405.34M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DLB | CPRT |
|---|---|---|
| Cash & Equivalents | $626.55M | $2.37B |
| Total Current Assets | $1.39B | $5.36B |
| Total Current Liabilities | $457.49M | $657.13M |
| Long-Term Debt | $29.66M | $81.27M |
| Total Shareholders Equity | $2.58B | $8.80B |
| Retained Earnings | $2.60B | $7.70B |
| Property, Plant & Equipment | $264.92M | $97.68M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DLB | CPRT |
|---|---|---|
| Operating Cash Flow | $129.41M | $704.64M |
| Capital Expenditures | $-6.90M | $-124.08M |
| Free Cash Flow | $168.00M | $572.92M |
| Debt Repayment | N/A | $-4,000 |
| Common Stock Repurchase | $-36.51M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DLB | CPRT |
|---|---|---|
| Shares Short | 1.45M | 28.63M |
| Short Ratio | 3.72 | 3.62 |
| Short % of Float | 0.04% | 0.04% |
| Average Daily Volume (10 Day) | 358,840 | 5,940,840 |
| Average Daily Volume (90 Day) | 373,870 | 7,150,000 |
| Shares Outstanding | 95.39M | 962.97M |
| Float Shares | 60.46M | 886.48M |
| % Held by Insiders | 0.01% | 0.09% |
| % Held by Institutions | 0.96% | 0.87% |
Dividend Analysis & Yield Comparison: Dolby Laboratories vs Copart
| Metric | DLB | CPRT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |